Terms: = Head and neck cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Treatment
48 results:
1. Cetuximab treatment beyond Progression in Patients with Recurrent or Metastatic head and neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08).
Wang HM; Lou PJ; Yang MH; Chen TH; Lien MY; Lin JC; Chen JP; Lu WC; Lu HJ; Huang TL; Yen CJ; Wu SY; Wang HC; Hsieh MC
Target Oncol; 2024 Jan; 19(1):51-58. PubMed ID: 38285067
[TBL] [Abstract] [Full Text] [Related]
2. Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?
Alfieri S; Romanò R; Marceglia S; De Giorgi V; Peris K; Sollena P; Piccerillo A; Moro R; Gualdi G; Ascierto PA; Palla M; Paone M; Eibenschutz L; Spagnolo F; Queirolo P; Filippini DM; Cavalieri S; Resteghini C; Bergamini C; Manocchio A; Licitra L; Bossi P
Oncologist; 2024 May; 29(5):e699-e707. PubMed ID: 38127280
[TBL] [Abstract] [Full Text] [Related]
3. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Garon EB; Cho BC; Luft A; Alatorre-Alexander J; Geater SL; Kim SW; Ursol G; Hussein M; Lim FL; Yang CT; Araujo LH; Saito H; Reinmuth N; Medic N; Mann H; Shi X; Peters S; Mok T; Johnson M
Lung Cancer; 2023 Dec; 186():107422. PubMed ID: 37992595
[TBL] [Abstract] [Full Text] [Related]
4. Genetic variability in cisplatin metabolic pathways and outcome of locally advanced head and neck squamous cell carcinoma patients.
Ferreira AMC; Altemani JMC; Macedo LT; Lourenço GJ; Lima CSP
Sci Rep; 2023 Oct; 13(1):16762. PubMed ID: 37798436
[TBL] [Abstract] [Full Text] [Related]
5. Extra-mandibular Osteoradionecrosis after the treatment of head and neck cancer.
Kovarik PDE; Patil R; Cvek J; Kelly C; Jackson M; Mackenzie L; West N; Willis N; Kovarik JP; Banks R; Kennedy M; Adams J; Iqbal MS
Clin Oncol (R Coll Radiol); 2023 Sep; 35(9):e498-e505. PubMed ID: 37433701
[TBL] [Abstract] [Full Text] [Related]
6. Total tumor diameter is a better indicator of multifocal papillary thyroid microcarcinoma: A propensity score matching analysis.
Jiang KC; Lin B; Zhang Y; Zhao LQ; Luo DC
Front Endocrinol (Lausanne); 2022; 13():974755. PubMed ID: 36004348
[TBL] [Abstract] [Full Text] [Related]
7. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Rischin D; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Braña I; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Ishak WZW; Hong RL; Mendoza RG; Jia L; Chirovsky D; Norquist J; Jin F; Burtness B
Oral Oncol; 2022 May; 128():105815. PubMed ID: 35381576
[TBL] [Abstract] [Full Text] [Related]
8. SEOM-GEMCAD-ttd Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021).
Fernández-Montes A; Alcaide J; Alsina M; Custodio AB; Franco LF; Gallego Plazas J; Gómez-Martín C; Richart P; Rivera F; Martin-Richard M
Clin Transl Oncol; 2022 Apr; 24(4):658-669. PubMed ID: 35347573
[TBL] [Abstract] [Full Text] [Related]
9. Video assisted thoracoscopy or laparoscopy for enucleation of esophageal leiomyoma: A seven-year single center experience of 75 cases.
Pham DH; Nguyen ND; Do ML; Nguyen XH; Quach VK; Bretagnol F; Fingerhut A; Leroy J
J Visc Surg; 2022 Apr; 159(2):108-113. PubMed ID: 34446363
[TBL] [Abstract] [Full Text] [Related]
10. Predictive value of ercc2, ABCC2 and MMP2 of response and long-term survival in locally advanced head and neck cancer patients treated with chemoradiotherapy.
Duran G; Cruz R; Aguín S; Barros F; Giráldez JM; Bernárdez B; Zarra I; López-López R; Carracedo Á; Lamas MJ
Cancer Chemother Pharmacol; 2021 Nov; 88(5):813-823. PubMed ID: 34309735
[TBL] [Abstract] [Full Text] [Related]
11. Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma.
Lordick F; Al-Batran SE; Ganguli A; Morlock R; Sahin U; Türeci Ö
Gastric Cancer; 2021 May; 24(3):721-730. PubMed ID: 33755863
[TBL] [Abstract] [Full Text] [Related]
12. The DNA damage response network in the treatment of head and neck squamous cell carcinoma.
Psyrri A; Gkotzamanidou M; Papaxoinis G; Krikoni L; Economopoulou P; Kotsantis I; Anastasiou M; Souliotis VL
ESMO Open; 2021 Apr; 6(2):100075. PubMed ID: 33714009
[TBL] [Abstract] [Full Text] [Related]
13. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
Hegde A; Andreev-Drakhlin AY; Roszik J; Huang L; Liu S; Hess K; Cabanillas M; Hu MI; Busaidy NL; Sherman SI; Dadu R; Grubbs EG; Ali SM; Lee J; Elamin YY; Simon GR; Blumenschein GR; Papadimitrakopoulou VA; Hong D; Meric-Bernstam F; Heymach J; Subbiah V
ESMO Open; 2020 Oct; 5(5):e000799. PubMed ID: 33097651
[TBL] [Abstract] [Full Text] [Related]
14. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid cancer: Results of a Randomized, Multicenter Phase II Trial.
Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
[No Abstract] [Full Text] [Related]
15. ercc2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
Guberina M; Sak A; Pöttgen C; Tinhofer-Keilholz I; Budach V; Balermpas P; Von der Grün J; Rödel CM; Gkika E; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; De-Colle C; Welz S; Linge A; Lohaus F; Baretton G; Gauler T; Baumann M; Krause M; Schuler M; Bankfalvi A; Höing B; Lang S; Stuschke M
Pharmacogenomics J; 2021 Feb; 21(1):37-46. PubMed ID: 32546699
[TBL] [Abstract] [Full Text] [Related]
16. xpd inhibits cell growth and invasion and enhances chemosensitivity in esophageal squamous cell carcinoma by regulating the PI3K/AKT signaling pathway.
Jian J; Li S; Liu LZ; Zhen L; Yao L; Gan LH; Huang YQ; Fang N
Int J Mol Med; 2020 Jul; 46(1):201-210. PubMed ID: 32377720
[TBL] [Abstract] [Full Text] [Related]
17. Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.
Smyth E; Zhang S; Cunningham D; Wotherspoon A; Soong R; Peckitt C; Valeri N; Fassan M; Rugge M; Okines A; Allum W; Stenning S; Nankivell M; Langley R; Tan P
Clin Cancer Res; 2017 Dec; 23(24):7543-7549. PubMed ID: 28972045
[No Abstract] [Full Text] [Related]
18. GSTP1 c.313A>G, xpd c.934G>A, XPF c.2505T>C and CASP9 c.-1339A>G Polymorphisms and Severity of Vomiting in head and neck cancer Patients treated with Cisplatin Chemoradiation.
Carron J; Lopes-Aguiar L; Costa EFD; Nogueira GAS; Lima TRP; Pincinato EC; Visacri MB; Quintanilha JCF; Moriel P; Lourenço GJ; Lima CSP
Basic Clin Pharmacol Toxicol; 2017 Dec; 121(6):520-525. PubMed ID: 28686330
[TBL] [Abstract] [Full Text] [Related]
19. Total tumour diameter is superior to unifocal diameter as a predictor of papillary thyroid microcarcinoma prognosis.
Liu C; Wang S; Zeng W; Guo Y; Liu Z; Huang T
Sci Rep; 2017 May; 7(1):1846. PubMed ID: 28500312
[TBL] [Abstract] [Full Text] [Related]
20. Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy.
Zhou F; Zhu M; Wang M; Qiu L; Cheng L; Jia M; Xiang J; Wei Q
J Transl Med; 2016 May; 14(1):154. PubMed ID: 27246611
[TBL] [Abstract] [Full Text] [Related]
[Next]
